Helen M R Robinson

6PUBLICATIONS
89CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 22, 2026
Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations.

|Jul 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

|Jun 12, 2026
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.

|Dec 08, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Eeson Rajendra, Claudio A Lademann, Bethany Mason

|Feb 28, 2024
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.

Patrick G Pilié, Virginia Giuliani, Wei-Lien Wang

|Jan 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.

Gonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo

Pageof 1

Frequent Collaborators

5 joint publications

Eeson Rajendra

4 joint publications

Marco Ranzani

4 joint publications

Graeme C M Smith

4 joint publications

Jayesh Majithiya